DRR168592
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- INTERFERON_ALPHA_RESPONSE+0.390
- COMPLEMENT+0.370
- PROTEIN_SECRETION+0.370
- FATTY_ACID_METABOLISM+0.350
- COAGULATION+0.310
- E2F_TARGETS+0.310
Top 10 suppressed
- TGF_BETA_SIGNALING-0.390
- WNT_BETA_CATENIN_SIGNALING-0.300
- MYC_TARGETS_V2-0.240
- UV_RESPONSE_DN-0.180
- KRAS_SIGNALING_DN-0.160
- TNFA_SIGNALING_VIA_NFKB-0.140
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.130
- HYPOXIA-0.130
- MYOGENESIS-0.130
- APICAL_JUNCTION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-K4-A5RJ-01A-11R-A28M-07 | — | — | 0.830 |
| 2 | 49df6599-2159-457c-a94f-980cab788dbf | — | — | 0.783 |
| 3 | TCGA-A2-A0SW-01A-11R-A084-07 | — | C | 0.780 |
| 4 | TCGA-E7-A7DV-01A-11R-A33J-07 | — | — | 0.759 |
| 5 | 608d8ca8-8eeb-40a1-a95b-57eefcabbdab | — | — | 0.755 |
| 6 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.752 |
| 7 | TCGA-39-5011-01A-01R-1443-07 | — | cohortA1 | 0.751 |
| 8 | ff02e85e-2f87-4832-aaea-3322db33c57a | — | — | 0.748 |
| 9 | TCGA-A8-A094-01A-11R-A00Z-07 | — | C | 0.745 |
| 10 | AUR-AERW-TTM1-A-1-1-R-A742-41 | — | C | 0.738 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.390 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.290 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |